50 terminated. 50 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 50 | Terminated 50 |
| Phase 2 | 15 | Terminated 15 |
Follow Bronchial Diseases: new trials by email Literature Review of Bronchial Diseases trials Research Report on Bronchial Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Upfront Ruxolitinib for Chronic Graft-vs-host Disease Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Terminated | Children's Hospital Medical Center, Cincinnati | 1 | 2025-02-19 | 2026-02-25 |
| A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma Briquilimab, Placebo Comparator - Allergic Asthma | Phase 1 | Terminated | Jasper Therapeutics, Inc. | 17 | 2024-11-26 | 2025-09-16 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
| Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Prednisone - Asthma | Phase 1 | Terminated | Emory University | 1 | 2022-03-16 | 2025-06-03 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations BLU-451, Carboplatin, Pemetrexed - Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 103 | 2022-03-04 | 2025-02-10 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma Zavegepant, Placebo - Asthma | Phase 1 | Terminated | Pfizer | 45 | 2021-10-18 | 2024-07-19 |
| Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant Itacitinib, Itacitinib Adipate - Bronchiolitis Obliterans | Phase 1 | Terminated | M.D. Anderson Cancer Center | 8 | 2021-10-08 | 2025-11-10 |
| First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 LQ036, Matching Placebo - Asthma | Phase 1 | Terminated | Syneos Health | 40 | 2021-09-06 | 2023-04-13 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
| A Trial of SHR-1703 in Healthy Subjects SHR-1703, Placebo - Asthma | Phase 1 | Terminated | Atridia Pty Ltd. | 1 | 2021-06-14 | 2021-12-01 |
| Evaluation of AZD8154 Concentrations in Blood AZD8154 nebuliser, AZD8154 Monodose DPI presented in capsules, AZD8154 Placebo Monodose DPI presented in capsules - Asthma | Phase 1 | Terminated | AstraZeneca | 10 | 2020-07-17 | 2021-08-24 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Itacitinib - Bronchiolitis Obliterans Syndrome | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 23 | 2020-02-04 | 2025-10-20 |
| Glasdegib for Chronic Graft-Versus-Host Disease Glasdegib - Chronic Graft Versus Host Disease, Fasciitis | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 15 | 2019-12-03 | 2024-10-29 |
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia rhIL-15, Obinutuzumab - Leukemia, Lymphocytic | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2019-07-11 | 2022-03-22 |
| A Study of MRx-4DP0004 in Asthma MRx-4DP0004, Placebo - Asthma | Phase 1 | Terminated | 4D pharma plc | 34 | 2019-07-04 | 2024-04-17 |
| Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT Ibrutinib, Rituximab - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Terminated | Dartmouth-Hitchcock Medical Center | 2 | 2019-04-11 | 2023-11-28 |
| Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma Roflumilast, Placebo - Asthma | Phase 1 | Terminated | University of California, Davis | 5 | 2019-01-21 | 2023-10-24 |
| Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide - Chronic Obstructive Pulmonary Disease, Asthma | Phase 1 | Terminated | Chiesi Farmaceutici S.p.A. | 19 | 2019-01-14 | 2022-05-06 |
| Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04 Aerosolized Infasurf - Bronchiolitis | Phase 1 | Terminated | ONY | 13 | 2019-01-12 | 2020-10-23 |
Showing 20 of 50. Sign in to see all of them.
Asthma (32) · Bronchiolitis Obliterans Syndrome (10) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Adenocarcinoma (3) · Bronchial Neoplasms (3) · Bronchiectasis (3) · Carcinoma (3) · Carcinoma, Bronchogenic (3) · Carcinoma, Non-Small-Cell Lung (3) · Hypersensitivity (3) · Lung Neoplasms (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3)
Respiratory Tract Diseases (46) · Lung Diseases (44) · Lung Diseases, Obstructive (43) · Immune System Diseases (41) · Hypersensitivity, Immediate (31) · Respiratory Hypersensitivity (31) · Hypersensitivity (29) · Bronchitis (12) · Bronchiolitis (11) · Bronchiolitis Obliterans (10) · Organizing Pneumonia (10) · Graft vs Host Disease (9) · Pathological Conditions, Signs and Symptoms (7) · Disease Attributes (6)
Carboplatin (2) · Epinephrine (2) · INCB039110 (2) · Pemetrexed (2) · Prednisolone (2) · itacitinib (2) · osimertinib (2) · ASM-024 (1) · Acupuncture Therapy (1) · Albuterol (1) · Antigens, Dermatophagoides (1) · BASS2 protein, Arabidopsis (1) · Bronchoscopy (1) · Capsules (1) · Control Groups (1)
GlaxoSmithKline (4) · AstraZeneca (3) · Blueprint Medicines Corporation (3) · Amphastar Pharmaceuticals, Inc. (2) · John Sundy (2) · M.D. Anderson Cancer Center (2) · 4D pharma plc (1) · Alaxia SAS (1) · Amgen (1) · Arrowhead Pharmaceuticals (1) · Asmacure Ltée (1) · Atridia Pty Ltd. (1) · Chiesi Farmaceutici S.p.A. (1) · Children's Hospital Medical Center, Cincinnati (1) · Dartmouth-Hitchcock Medical Center (1)
United States (29) · United Kingdom (11) · Canada (8) · Australia (3) · South Korea (3) · Taiwan (3) · France (2) · Japan (2) · Poland (2) · Spain (2) · Thailand (2) · Belgium (1) · Brazil (1) · China (1) · Germany (1)
Ada C. Gastaldi, doctor (1) · Alessio Fasano, M. D. (1) · Amin Alousi, MD (1) · Christopher Brightling, Professor (1) · Christopher O'Brien, MD, PhD, FCCP (1) · Dave Singh (1) · David Kaminsky, MD (1) · Donald Tashkin, M.D. (1) · Dr Richard Friend (1) · Edwin Horwitz, MD (1) · Huaiyu Gu (1) · Isabelle Durieu, Prof., MD (1) · Jim Shi, M.D., Ph.D. (1)
PMID 29550052, PMID 11978924, PMID 1280928, PMID 24995515, PMID 28733314, PMID 28800383, PMID 32150492, PMID 32508818, PMID 33314326, PMID 33883258, PMID 35128939, PMID 37698881, PMID 9674466
2009 (1), 2014 (1), 2015 (1), 2017 (1), 2019 (1), P01AT002647 (1), R21AT004089 (1)